

Fig. S1. Sensitivity analysis of relative contribution of itch and Psoriasis Area and Severity Index (PASI) scores on Dermatology Life Quality Index (DLQI) symptom and feelings domain score change at Week 4 and Week 12. ETN: etanercept; IXE Q2W: ixekizumab 80mg once every 2 weeks; IXE Q4W: ixekizumab 80mg once every 4 weeks; PBO: placebo.




Fig. S2. Sensitivity analysis of relative contribution of itch and Psoriasis Area and Severity Index (PASI) scores on change in Dermatology Life Quality Index (DLQI) total score without symptoms and feelings domain score at Week 4 and Week 12. ETN: etanercept; IXE Q2W: ixekizumab 80mg once every 2 weeks; IXE Q4W: ixekizumab 80mg once every 4 weeks; PBO: placebo.

Table SI. Patient demographics and baseline characteristics

Parameter	PBO n = 361	ETN n = 740	IXE Q4W n = 733	IXE Q2W n = 736
Age, years, mean (SD)	45.9 (12.1)	45.5 (13.3)	45.3 (13.1)	45.1 (13.2)
Male, n (%)	257 (71.2)	505 (68.2)	502 (68.5)	475 (64.5)
Race, n (%)				
White	325 (90.0)	682 (92.7)	675 (92.6)	691 (94.0)
African American	18 (5.0)	23 (3.1)	20 (2.7)	10 (1.4)
Asian	13 (3.6)	19 (2.6)	22 (3.0)	24 (3.3)
Native Hawaiian or Other	1 (0.3)	2 (0.3)	2 (0.3)	4 (0.5)
American Indian or Alaska Native	3 (0.8)	4 (0.5)	6 (0.8)	3 (0.4)
Multiple	1 (0.3)	6 (0.8)	4 (0.5)	3 (0.4)
Duration of psoriasis (years), mean (SD)	18.62 (12.6)	18.50 (12.1)	18.49 (12.6)	18.06 (12.2)
Previous systemic therapy, yes, n (%)	209 (57.9)	447 (60.4)	456 (62.2)	440 (59.8)
Prior biologic therapy, yes, n (%)	76 (21.1)	136 (18.4)	143 (19.5)	142 (19.3)
PASI Score, mean (SD)	20.86 (8.4)	19.90 (7.5)	20.62 (7.6)	20.07 (7.8)
Itch NRS Score, mean (SD)	6.4 (2.7)	6.4 (2.6)	6.4 (2.6)	6.5 (2.6)
DLQI Score, mean (SD)	12.8 (7.1)	12.0 (7.0)	11.8 (6.8)	12.4 (6.9)
Joint Pain VAS, mean (SD)	52.9 (25.8)	47.9 (30.9)	50.0 (28.3)	48.2 (28.4)

DLQI: Dermatology Life Quality Index; ETN: etanercept; IXE Q2W: ixekizumab 80 mg once every 2 weeks; IXE Q4W: ixekizumab 80 mg once every 4 weeks; PASI: Psoriasis Area and Severity Index; PBO: placebo; SD: standard deviation; VAS: visual analogue scale.

Table SII. Outcomes in Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and improvement in itch and Dermatology Life Quality Index (DLQI) scores at Weeks 4 and 12

Parameter	Week 4				Week 12			
	PBO	ETN	IXE Q4W	IXE Q2W	PBO	ETN	IXE Q4W	IXE Q2W
PASI 75, %	1.7	9.9**	50.3***††	51.9***††	5.0	47.7**	81.0***††	88.5***††
PASI 90, %	0.3	2.2*	23.9***††	22.3***††	1.9	22.3**	62.6***††	69.3***††
PASI 100, %	0	0.4	6.0***††	8.2***††	0.3	6.4**	33.0***††	39.0***††
DLQI (0,1), %	7.2	18.8**	43.5***††	39.3***††	6.9	38.9**	61.9***††	64.4***††
Itch NRS, LS, mean (SE)	-0.4 (0.12)	-2.4 (0.08)**	-4.1 (0.08)***††	-4.2 (0.08)***††	-0.5 (0.12)	-3.8 (0.08)**	-4.9 (0.08)***††	-5.2 (0.08)***††
Itch NRS=0, %	2.8	7.3*	22.9***††	21.2***††	3.9	19.5**	40.2***††	43.1***††
Itch NRS ≤3, %	21.9.	50.0.**	76.1.**††	77.7.**††	27.4.	71.8**	85.5.**††	89.8.**††
DLQI Total Score, LS, mean (SE)	-1.9 (0.22)	-5.7 (0.16)**	-8.3 (0.16)***††	-8.5 (0.16)***††	-1.8 (0.24)	-7.8 (0.17)**	-9.5 (0.17)***††	-10.3 (0.17)***††
Symptoms and feelings, mean (SE)	-0.7 (0.06)	-1.6 (0.04)**	-2.5 (0.04)***††	-2.4 (0.04)***††	-0.5 (0.06)	-2.2 (0.04)**	-2.8 (0.05)***††	-3.0 (0.04)***††
Daily activities	-0.5 (0.06)	-1.2 (0.04)**	-1.9 (0.04)***††	-1.8 (0.04)***††	-0.4 (0.06)	-1.7 (0.04)**	-2.1 (0.04)***††	-2.3 (0.04)***††
Leisure	-0.5 (0.06)	-1.1 (0.04)**	-1.5 (0.04)***††	-1.5 (0.04)***††	-0.4 (0.06)	-1.4 (0.04)**	-1.7 (0.04)***††	-1.8 (0.04)***††
Work and school	-0.2 (0.03)	-0.5 (0.02)**	-0.6 (0.02)***††	-0.6 (0.02)***††	-0.2 (0.03)	-0.6 (0.02)**	-0.7 (0.02)**	-0.8 (0.02)***††
Personal relationships	-0.0 (0.05)	-0.8 (0.04)**	-1.2 (0.04)***††	-1.2 (0.04)***††	-0.1 (0.06)	-1.1 (0.04)**	-1.3 (0.04)***††	-1.4 (0.04)***††
Treatment	-0.1 (0.03)	-0.5 (0.02)**	-0.8 (0.02)***††	-0.8 (0.02)***††	-0.1 (0.03)	-0.7 (0.02)**	-0.9 (0.02)***††	-0.9 (0.02)***††

* $p < 0.05$, ** $p < 0.001$ vs PBO; † $p < 0.01$, †† $p < 0.001$ vs ETN. LS: least square; NRS: Numeric Rating Scale; SE: standard error; ETN: etanercept; IXE Q2W: ixekizumab 80 mg once every 2 weeks; IXE Q4W: ixekizumab 80 mg once every 4 weeks.